Cantor Fitzgerald Reiterates a Buy Rating on HCA Healthcare (HCA) With a $444 PT

HCA Healthcare, Inc. (NYSE:HCA) is one of the best medical stocks to buy now. In a report released on September 26, Sarah James from Cantor Fitzgerald reiterated a Buy rating on HCA Healthcare, Inc. (NYSE:HCA) and set a price target of $444.00.

Jim Cramer Is Worried About HCA Healthcare, Inc. (HCA) Due To Medicaid Cuts

HCA Healthcare, Inc. (NYSE:HCA) reported a 6.4% growth in its revenues for fiscal Q2 2025 to $18.605 billion, while net income attributable to the company rose 13.1% to $1.653 billion.

Management further reported that diluted EPS rose 23.5% to $6.83 per diluted share, while diluted EPS, as adjusted, grew 24.4% to $6.84 per diluted share. Adjusted EBITDA also rose 8.4% to $3.849 billion.

HCA Healthcare, Inc. (NYSE:HCA) is a health care services company involved in the operation of hospitals, urgent care facilities, freestanding surgery centers and emergency care facilities, diagnostic and imaging centers, walk-in clinics, radiation and oncology therapy centers, and more.

While we acknowledge the potential of HCA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than HCA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.